Lupus Nephritis

The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases the requirement for monthly kidney function assessments.

This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.

The FDA has cleared an investigational new drug application for an allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of systemic lupus erythematosus with lupus nephritis, according to the manufacturer.

Kidney Disease: Improving Global Outcomes has released a revised clinical practice guideline for the treatment of lupus nephritis.

The FDA has granted fast track designation for an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate to treat those with refractory progressive multiple sclerosis, according to the manufacturer.

The FDA has granted fast track designation for KYV-101, an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, to treat myasthenia gravis.

An organ procurement organization and a patient support and advocacy group will have floats in the 2024 Tournament of Roses Parade promoting organ donation and to spread awareness about kidney health screening.

The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone equivalent or less, according to the updated 2023 EULAR recommendations for the management of systemic lupus erythematosus.

SAN DIEGO — Improving hydroxychloroquine use and reducing glucocorticoid exposure are among the top priorities of the Healthy People with Lupus 2030 initiative, which aims to address care disparities, said a speaker at ACR Convergence 2023.

SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.